中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 药物制剂研究中心
Protease-Activatable Hybrid Nanoprobe for Tumor Imaging

文献类型：期刊论文

作者Wang, Yaping1,2; Jiang, Yifan2; Zhang, Meng2; Tan, Jiao2; Liang, Jianming2; Wang, Huixin2; Li, Yaping2; He, Huining1; Yang, Victor C.1,3; Huang, Yongzhuo2
刊名ADVANCED FUNCTIONAL MATERIALS
出版日期2014-09-10
卷号24期号:34页码:5443-5453
ISSN号1616-301X
DOI10.1002/adfm.201400419
文献子类Article
英文摘要Tumor-associated proteases (TAPs), such as legumain, are actively involved in cancer progression; they have been used as biomarkers for diagnosis, prognosis, and drug targeting. As a result, in-vivo detection and trafficking of TAPs have attracted a great deal of attention. TAP-specific probes for in-vivo imaging, however, remain rare. A TAP-responsive hybrid nanoprobe system based on quantum dots (QD) and the fluorescence resonance energy transfer (FRET) effect is presented for the detection of legumain (asparaginyl endopeptidase), which is overexpressed in many tumors. A novel hybrid construction method is developed for fabricating the nanoprobe, by which the strong heparin-protamine affinity is used for conjugation. The hybrid comprises two components: 1) low-molecular-weight heparin (LH)-modified QD, and 2) low-molecular-weight protamine (LMWP)-conjugated fluorescence quencher QSY21, through a legumain-cleavable linker. The hybrid nanoprobe (i.e., a FRET system) is self-assembled via the LH-LMWP affinity. The linker between LMWP and QSY21 is selectively cleaved by legumain, leading to QSY21 detachment and fluorescence recovery in the tumor. In-vivo imaging is successfully achieved in the colon tumor mouse model. Importantly, such a hybrid nanoprobe system is adaptable for the detection of other TAPs (e. g., matrix metalloproteinase -2) by using an established, corresponding substrate-peptide linker, thereby offering a universal platform for TAP detection and tumor imaging.
WOS关键词DRUG-DELIVERY ; BREAST-CANCER ; LEGUMAIN ; DIAGNOSIS ; STRATEGY ; CELLS
资助项目National Basic Research Program of China (973 Program)[2014CB931900] ; National Basic Research Program of China (973 Program)[2013CB932503] ; NSFC, China[91029743] ; NSFC, China[81172996] ; NSFC, China[81373357] ; NSFC, China[81361140344]
WOS研究方向Chemistry ; Science & Technology - Other Topics ; Materials Science ; Physics
语种英语
WOS记录号WOS:000341834000015
出版者WILEY-V C H VERLAG GMBH
源URL[http://119.78.100.183/handle/2S10ELR8/276907]  
专题药物制剂研究中心
通讯作者Wang, Yaping
作者单位1.Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin 300070, Peoples R China;
2.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China;
3.Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA
推荐引用方式
GB/T 7714		 Wang, Yaping,Jiang, Yifan,Zhang, Meng,et al. Protease-Activatable Hybrid Nanoprobe for Tumor Imaging[J]. ADVANCED FUNCTIONAL MATERIALS,2014,24(34):5443-5453.
APA Wang, Yaping.,Jiang, Yifan.,Zhang, Meng.,Tan, Jiao.,Liang, Jianming.,...&Huang, Yongzhuo.(2014).Protease-Activatable Hybrid Nanoprobe for Tumor Imaging.ADVANCED FUNCTIONAL MATERIALS,24(34),5443-5453.
MLA Wang, Yaping,et al."Protease-Activatable Hybrid Nanoprobe for Tumor Imaging".ADVANCED FUNCTIONAL MATERIALS 24.34(2014):5443-5453.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。